Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 1,2-benzisoxazole-3-13C-3-methane-13C-sulfonamide-15N
- Correlated keywords
- CI-912 PD 110843 PD110843 CI912 Zonegran Exceglan Excegram Excegran AD810 isotope C-13 N-15 C13 C15 GCMS LCMS anti-epileptic Helicobacter convulsant electro-shock
- Product Overview:
Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide (Item No. 24183) by GC- or LC-MS. Zonisamide is an antiepileptic agent.{41543} It selectively inhibits the repeated firing of sodium channels (IC50 = 2 ?g/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 ?g/ml.{41545} In rat cerebral cortex neurons, zonisamide (1-1,000 ?M) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.{41546} Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.{33180,41544} In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine (Item No. 21992), but not homovanillic acid (HVA; Item No. 27307) or dihydroxyphenyl acetic acid (DOPAC; Item No. 24912), and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson’s disease.{45492} Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.